Bionano Genomics says OGM ‘exclusively detects alterations in known oncogenes’

Bionano Genomics announced the publication of a peer-reviewed study that compared optical genome mapping OGM to classical cytogenetic techniques used for analysis of solid tumor cancer samples consisting of soft tissue and bone sarcomas, including fluorescence in situ hybridization FISH and karyotyping KT. OGM demonstrated high levels of concordance with FISH and KT but was also shown to exclusively detect alterations in known oncogenes and tumor suppressor genes and to identify additional pathogenic aberrations, including chromothripsis and chromoplexy, that were not detected by multiple other cytogenetic methods…”Characterization of sarcoma is enormously challenging and requires several different techniques, which often yield equivocal results that don’t explain the underlying disorder. We are pleased to see results from this study on the use of OGM to investigate sarcomas, which provided the study authors with insights into the genomic complexity underlying various aberrations, highlighting the high sensitivity and robustness of our workflow and enhancing our understanding of tumor biology.? We believe this study is an important advancement for OGM and for the cancer research community as it now illustrates the utility of OGM not only in cancer, but in an important solid tumor,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.